<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205411</url>
  </required_header>
  <id_info>
    <org_study_id>CAP00030</org_study_id>
    <nct_id>NCT02205411</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the HeartAssist 5® VAD System Compared to the Thoratec HeartMate II® VAD and HeartWare® HVAD for Left Ventricular Support in Patients Awaiting Cardiac Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReliantHeart Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReliantHeart Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart
      HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death
      from refractory end-stage heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HeartAssist 5® VAD System is intended for use as a bridge to heart transplantation and
      will be compared to the HeartMate II and HVAD devices.

      Patients that meet the study criteria will be randomized 1:1 to either the HeartAssist 5® VAD
      System (treatment group) or control group (HeartMate II and HVAD). The physician will have
      the option to choose which control device to implant.

      The primary objective of the study is to show non-inferiority of the HeartAssist 5®
      (treatment group) to the control group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is success at 180 days</measure>
    <time_frame>180 days</time_frame>
    <description>Success at 180 days is defined as alive on the original device, transplanted or explanted for heart recovery and alive 60 days after device explant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>180 days</time_frame>
    <description>Device safety will be reported as the frequency of each adverse event, (including device failure, device malfunction or unanticipated adverse device effects) and the rate of adverse events per patient year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>180 days</time_frame>
    <description>Quality of life data, as measured by the EuroQol (EQ-5D) will be summarized and analyzed, for both groups, comparing data at baseline and study intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>180 days</time_frame>
    <description>NYHA and six-minute walk analysis will be reported by group for data at pre-implant and at study-defined intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic Status</measure>
    <time_frame>180 days</time_frame>
    <description>Evaluation of any change in Modified Rankin Scale from baseline to 180-days post-implant or device explant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiac Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Heart Failure, Left-sided</condition>
  <arm_group>
    <arm_group_label>HeartAssist 5® VAD System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of the HeartAssist 5® VAD System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control VAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartAssist 5® VAD System</intervention_name>
    <description>The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.</description>
    <arm_group_label>HeartAssist 5® VAD System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control VAD</intervention_name>
    <description>The HeartMate II® VAD or HVAD®</description>
    <arm_group_label>Control VAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to sign Informed Consent.

          2. Age ≥ 18

          3. Body Surface Area (BSA) ≥ 1.2 m2.

          4. Cardiac transplant candidate, defined as: Listed for cardiac transplant, and
             designated by the institution's multidisciplinary transplant committee as appropriate
             forLVAD Bridge-to-Transplantation therapy, or Designated by the institutions's
             multidisciplinary transplant committee as: 1) an appropriate candidate for LVAD
             Bridge-to transplant therapy, and 2) An inappropriate candidate for LVAD destination
             therapy

          5. LVAD implantation has been approved by the institution's multidisciplinary transplant
             committee.

          6. Patient is NYHA Class IV.

          7. Able to return to the clinical site for all routine follow up visits.

        Exclusion Criteria:

          1. Cardiothoracic surgery within 30 days prior to enrollment.

          2. Acute Myocardial Infarction within 14 days prior to enrollment.

          3. Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty or
             left ventricular assist device.

          4. Mechanical, animal, or human tissue heart valve.

          5. History of untreated abdominal or thoracic aortic aneurysm &gt; 5 cm.

          6. On ventilator support for &gt; 72 hours within four days immediately prior to enrollment.

          7. Ongoing mechanical circulatory support other than an intra-aortic balloon pump (IABP).

          8. Proven history of pulmonary embolism within 90 days of enrollment.

          9. Moderate to severe aortic insufficiency as determined by echocardiogram without plans
             for correction during pump implantation surgery.

         10. Requires aortic, mitral, tricuspid or pulmonary valve replacements (including
             Bioprosthetic valves) or left ventricular (LV) aneurysm resection.

         11. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelets &lt;100,000,
             INR &gt; 1.6 or PTT &gt; 2.5 times control in the absence of anticoagulation therapy)

         12. Severe right ventricular failure as defined by the anticipated need for right
             ventricular assist device (RVAD) support OR extracorporeal membrane oxygenation (ECMO)
             at the time of implantation OR right atrial pressure &gt; 20 mmHg while on multiple
             inotropes.

         13. Significant renal dysfunction defined as &gt; 3.5 mg/dl or requires hemo or peritoneal
             dialysis for renal failure (excluding ultra-filtration for fluid removal).

         14. Evidence of intrinsic hepatic disease defined as liver enzyme values (AST, ALT and LDH
             that are &gt; 3 times the upper limit of normal) OR a total bilirubin &gt; 3 mg/dl OR biopsy
             proven liver cirrhosis or portal hypertension.

         15. Pregnancy

         16. Active systemic infection prior to study enrollment not yet resolved by treatment.
             Active Systemic Infection is defined by any one of the following in spite of
             antibiotic, antiviral or antifungal treatment: 2 or more consecutive positive
             cultures; elevated temperature &gt; 37.2 (°C) and white blood cell count &gt; 11.0 (103/ml);
             hypotension, tachycardia and generalized malaise.

         17. Stroke within 90 days prior to enrollment OR patient has a history of cerebral
             vascular disease with &gt; 80% extra cranial stenosis documented by carotid Doppler study
             during transplant evaluation

         18. Modified Rankin Scale score of ≥ 2 or has any neurologic disability as confirmed by
             imaging (CT or MRI).

         19. Significant lower extremity peripheral vascular disease accompanied by rest pain or
             leg ulceration.

         20. Intolerant to anticoagulant or antiplatelet therapies or any other peri- or
             postoperative therapy that the investigator may administer based upon the patient's
             health status.

         21. Psychiatric disorder, or other psychosocial behavior that is likely to impair
             compliance with the study protocol.

         22. Receiving therapy with an investigational intervention or participating in any other
             clinical investigation at the time of enrollment.

         23. Condition, other than heart failure, that may limit survival to less than three (3)
             years and/or would exclude cardiac transplantation.

         24. Unwilling or unable to comply with any study requirement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bryan Lynch</last_name>
    <phone>713-457-1388</phone>
    <email>blynch@reliantheart.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lowe, Coordinator</last_name>
      <email>David.Lowe@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>George Wieselhaler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kokil Bakshi, Coordinator</last_name>
      <email>kbakshi@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sandra Chaparro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becki Pisarski</last_name>
      <email>bpisarski@surgery.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Valluvan Jeevanandam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health, Inc. d/b/a Methodist Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>I-Wen Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital &amp; Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Margiotti, CRC</last_name>
      <phone>317-338-6151</phone>
      <email>ramargio@stvincent.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Schleeter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Blanton</last_name>
      <email>mary.blanton@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Slaughter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Thomas, coordinator</last_name>
      <email>Kari.M.Thomas@allina.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital - Saint Mary's Campus</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Faust, RN</last_name>
      <phone>507-255-8605</phone>
      <email>faust.julie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Lyle Joyce, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pavan Alturi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI St. Luke's Baylor College of Medicine Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Parker, Coordinator</last_name>
      <email>aparker@texasheart.org</email>
    </contact>
    <investigator>
      <last_name>Steve Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Prystash, RN</last_name>
      <phone>713-441-3910</phone>
      <email>mlprystash@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Brian Bruckner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella N Candelaria</last_name>
      <email>Isabella.N.Candelaria@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Igor Gregoric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Passey, RN</last_name>
      <email>lisa.passey@providence.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Icenogle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart assist device</keyword>
  <keyword>ventricular assist device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

